Entia Biosciences, Inc. 4/A
4/A · Entia Biosciences, Inc. · Filed Dec 31, 2013
Insider Transaction Report
Form 4/AAmended
HAUSMAN MARVIN S MD
DirectorCEO10% Owner
Transactions
- Purchase
Series A Preferred Stock
2013-06-11$5.00/sh+16,025$80,125→ 21,025 totalExercise: $0.50From: 2013-06-11→ Common Stock (160,250 underlying) - Purchase
Series A Preferred Stock
2013-01-17$5.00/sh+1,000$5,000→ 5,000 totalExercise: $0.50From: 2013-05-30→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The conversion price is adjustable pursuant to certain anti-dilution provisions.
- [F2]The preferred shares are convertible into common shares at any time, but under certain circumstances there could be a mandatory conversion, as for example after the annivesary of the effectiveness of a registration statement covering the common stock underlying the preferred shares or within 30 days of the closing of a private placement exceeding $5 million.
- [F3]Dr. Hausman acquired these preferred shares by converting a promissory note in the amount of $30,125 (principal plus accrued interest) and $50,000 payable to Dr. Hausman for travel and related expenses.